Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Provexis plc is a public limited company specializing in the development, licensing, and commercialization of innovative functional food ingredients, particularly its proprietary Fruitflow technology. Fruitflow, a natural tomato extract available in syrup and powder forms, helps maintain normal platelet aggregation to support healthy blood flow, reducing the risk of aberrant clotting associated with cardiovascular conditions like heart attacks and strokes. Clinically validated in human trials, it offers effects similar to low-dose aspirin but without side effects, and is the only natural antiplatelet with an approved health claim by the European Food Safety Authority. Provexis plc sells Fruitflow directly to food, beverage, and supplement manufacturers worldwide, alongside products like Fruitflow+ Omega-3 via its e-commerce site and retailers. Founded in 1999 to commercialize research from the Rowett Research Institute, the company listed on AIM in 2005 and is headquartered in Reading, United Kingdom. Key partnerships include long-term supply agreements with DSM Nutritional Products and BYHEALTH for expansion into markets like China, where regulatory approvals for new health claims are advancing. Fruitflow's applications extend to mitigating exercise-induced inflammation, managing blood pressure, countering air pollution effects, and modulating the gut microbiome to reduce cardiovascular risk factors.